Every 8-K that Coherus Oncology, Inc. (CHRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHRS filings page.
Coherus Oncology, Inc. (CHRS) entered into a sales agreement with Leerink Partners LLC allowing "at the market" issuances of its common stock with an aggregate offering price of up to $50.0 million. Leerink may act as sales agent or principal under a Form S-3 shelf registration declared effective on December 8, 2025.
Coherus will pay Leerink a commission of up to 3.0% of gross proceeds from each sale, and either party may terminate the agreement on ten days’ notice. Coherus intends to use any net cash proceeds for general corporate purposes, including working capital.
Coherus Oncology, Inc. announced a special dividend of contingent value rights (CVRs) tied to its remaining biosimilar business. Stockholders of record of Coherus common stock at 5:00 p.m. Eastern Time on September 30, 2026 (the Record Date) will receive one CVR for each share held.
The CVRs will be distributed on October 7, 2026 and will entitle holders to their pro rata share of any net cash proceeds that Coherus actually receives from selling, licensing, or otherwise monetizing specified “Legacy BioSim Assets,” including patents, an existing royalty stream, cell lines and related materials, during the CVR term. The CVR term runs from October 7, 2026 through October 7, 2028; if no qualifying net proceeds are received in that period, the CVRs will expire without payment.
The CVRs are non-transferable except in limited cases, will not be certificated, carry no voting or dividend rights, and will not be listed or traded. Payments, if any, are subject to deductions for taxes and specified expenses and to restrictions in Coherus’ August 12, 2026 Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, L.P.
Coherus Oncology, Inc. entered into a new senior secured term loan facility of $55,000,000 with Innovatus Life Sciences Lending Fund I, LP and other lenders, maturing in August 2031. On August 14, 2026, Coherus drew the full Tranche A amount and used a portion to repay and terminate its prior senior secured term loan, which had been scheduled to mature in May 2029 and carried interest at 8.0% plus three‑month SOFR. Remaining proceeds are designated for working capital and general business requirements.
The new Term Loans bear a floating rate of 4.15% plus the greater of the Prime Rate or 6.75%, with an initial 36‑month interest‑only period, extendable to 48 months upon achieving specified revenue and market capitalization milestones. Coherus also has the option to draw additional tranches of $25,000,000 and $20,000,000 under certain conditions. The loans are secured by liens on substantially all borrower assets, include a minimum unrestricted cash covenant, facility and prepayment fees, and a 4.00% final fee that can increase to 10.00% if the company begins an insolvency proceeding and receives specified debtor‑in‑possession financing.
Coherus Oncology reported second quarter 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI, which generated $13.6 million in net revenue, 15% above the prior quarter. Cost of goods sold was $4.2 million, while R&D and SG&A expenses declined versus 2025 as the company reduced headcount and completed its exit from the biosimilar business.
The company recorded a GAAP net loss from continuing operations of $33.3 million, or $0.22 per share, compared with a $44.9 million loss, or $0.39 per share, in 2025; non-GAAP net loss narrowed to $30.1 million. Cash, cash equivalents and marketable securities totaled $105.3 million at June 30, 2026, down from $172.1 million at year-end 2025. Coherus highlighted clinical progress for tagmokitug and casdozokitug and anticipates publicly disclosing data sets with sufficient maturity in early October 2026.
Coherus Oncology, Inc. filed an 8-K reporting a change in its independent auditor. On June 12, 2026, the Audit Committee dismissed Ernst & Young LLP as the company’s independent registered public accounting firm. EY’s audit reports on the 2024 and 2025 financial statements contained no adverse opinions, disclaimers, or qualifications, and the company reports no disagreements or reportable events with EY, other than a previously disclosed material weakness in internal control over certain inventory reconciliations that has since been remediated.
On the same date, the Audit Committee selected PricewaterhouseCoopers LLP to serve as independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures. EY has been asked to provide, and has provided, a letter to the SEC agreeing with the company’s disclosures, which is included as Exhibit 16.1.
Coherus Oncology, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class III directors Dennis M. Lanfear and Mats L. Wahlström to serve until the 2029 annual meeting. At the record date on April 16, 2026 there were 154,217,609 common shares outstanding, each entitled to one vote.
Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved a non-binding Say-on-Pay resolution for executive compensation. They also approved a reduction in the exercise price of certain outstanding stock options and an increase in the shares reserved under the Amended and Restated 2014 Equity Incentive Award Plan, both equity-related items that can affect future dilution and employee incentives.
Coherus Oncology reported first quarter 2026 results showing early progress in its oncology transition. Net revenue from continuing operations was $12.3 million, up from $7.6 million a year earlier, driven by LOQTORZI net revenue of $11.8 million in the quarter.
GAAP net loss from continuing operations narrowed to $36.9 million, or $(0.27) per share, versus $47.4 million, or $(0.41) per share, with lower R&D and SG&A reflecting the 2025 exit from the biosimilar business. Non-GAAP net loss from continuing operations was $33.9 million, or $(0.25) per share. Cash, cash equivalents and marketable securities totaled $167.0 million as of March 31, 2026, while the company highlighted clinical progress for tagmokitug and casdozokitug alongside its LOQTORZI commercial ramp.
Coherus Oncology, Inc. reported 2025 results showing strong product growth alongside continued losses from continuing operations. LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024, helping lift total net revenue from continuing operations to $42.2 million from $26.4 million.
The company reduced secured and convertible debt by about 90% over 2024–2025, from $480 million to $38.8 million, and ended 2025 with $172.1 million in cash, cash equivalents and marketable securities. Research and development spending from continuing operations increased to $108.9 million, reflecting investment in pipeline candidates casdozokitug and tagmokitug, while selling, general and administrative expenses declined to $100.6 million.
Net loss from continuing operations for 2025 narrowed to $183.1 million, or $(1.56) per diluted share, from $215.4 million, or $(1.88) per share, in 2024. Including large gains from discontinued operations, Coherus reported full-year net income of $168.0 million for 2025 compared with $28.5 million in 2024.
Coherus Oncology, Inc. completed an underwritten public offering of its common stock. The company sold 28,600,000 shares at a price to the public of $1.75 per share, with underwriters purchasing at $1.645 per share, generating approximately $47.0 million in net proceeds before expenses.
The underwriters also received a 30-day option to buy up to an additional 4,290,000 shares to cover any over-allotments. Coherus, its directors, executive officers and certain affiliated stockholders agreed to a 60-day lock-up on additional common stock sales, subject to specified exceptions.
Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC to support a Phase 1b study in metastatic castration-resistant prostate cancer. The trial will evaluate Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody tagmokitug (CHS-114) in combination with Janssen’s T-cell engaging bispecific antibody pasritamig.
Under the agreement, Janssen will supply pasritamig, while Coherus will act as sponsor of the Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer. Each company keeps all commercial rights to its own compound, whether used alone or in combination therapies.
Coherus Oncology, Inc. filed a prospectus supplement tied to its existing Sales Agreement with TD Securities (USA) LLC (TD Cowen), allowing it to sell shares of common stock from time to time in an at-the-market offering program. The company may offer and sell common stock having an aggregate offering price of up to $64,880,054 through or to TD Cowen under this arrangement.
The filing also includes a legal opinion from Latham & Watkins LLP on the validity of the common stock to be issued under the Sales Agreement, along with the related consent and cover page interactive data file as exhibits.
Coherus Oncology, Inc. filed a current report to share that it is furnishing preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025. The company will present preliminary net revenues and levels of cash, cash equivalents and investments at the 43rd Annual J.P. Morgan Healthcare Conference, with this data included in a slide deck furnished as Exhibit 99.1.
Coherus stresses that its financial closing procedures for this period are not yet complete, so final results may differ materially from the preliminary figures, and its independent registered public accounting firm has not reviewed or audited these results. The presentation also contains forward-looking statements, including projected revenue growth of LOQTORZI, which the company notes are subject to significant risks such as financing needs, market acceptance of its products and litigation risks.
Coherus Oncology (CHRS) recast prior financials to reflect discontinued operations after divesting its UDENYCA franchise. The company completed the UDENYCA sale to Intas on April 11, 2025 for upfront, all‑cash consideration of $483.4 million, which included $118.4 million for product inventory. Coherus is also eligible for two additional earn‑out payments of $37.5 million each.
Exhibit 99.1 updates selected sections of the 2024 Form 10‑K to present the biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations for the fiscal years ended December 31, 2024 and 2023. The recast information is intended for incorporation by reference into a Form S‑3 expected to be filed on November 13, 2025. The filing limits changes to those necessary for the discontinued operations presentation, maintaining the nature and character of the original disclosures.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.
On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.